Alaunos Therapeutics, Inc.·4

Jun 26, 9:19 PM ET

Postma Robert W 4

4 · Alaunos Therapeutics, Inc. · Filed Jun 26, 2025

Insider Transaction Report

Form 4
Period: 2025-06-24
Transactions
  • Purchase

    Series A-1 Convertible Preferred Stock

    2025-04-11$2.76/sh+500$1,380500 total(indirect: By WaterMill Asset Management Corp.)
    Exercise: $2.76From: 2025-04-11Common Stock (181,159 underlying)
  • Award

    Common Stock

    2025-04-13$2.92/sh+20,804$60,74829,083 total
  • Purchase

    Series A-2 Convertible Preferred Stock

    2025-06-24$4.49/sh+600$2,694600 total(indirect: By Watermill Asset Management Corp)
    Exercise: $4.49From: 2025-06-24Common Stock (133,630.29 underlying)
Holdings
  • Common Stock

    (indirect: By WaterMill Asset Management Corp.)
    33,333
  • Common Stock

    (indirect: By Spouse)
    24
  • Employee Stock Option (right to buy)

    Exercise: $10.30Exp: 2034-06-05Common Stock (3,737 underlying)
    3,737
Footnotes (4)
  • [F1]The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill.
  • [F2]The preferred stock is perpetual and therefore has no expiration date.
  • [F3]The reporting person disclaims beneficial ownership of these equity securities to the extent that after giving effect of the conversion of the preferred stock and the underlying common stock issuance, the reporting person would beneficially own in the aggregate in excess of 4.99% of the outstanding shares immediately after giving effect to such conversion or issuance.
  • [F4]One-twelfth of the Option vests each month on the monthly anniversary of June 6, 2024, with any amount that remains unvested on the date immediately preceding the Company's 2025 annual general meeting of stockholders vesting thereon.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4